Leadership Change and Market Dynamics
resigns as CEO of after eight years, facing pressure from the and a significant drop in share price due to market challenges.
Competition from 's obesity drugs, particularly a promising one-daily weight loss pill, intensifies the market struggle for Novo Nordisk's and Ozempic.
Financial Performance and Strategic Responses
Novo Nordisk revises down its 2025 sales and operating profit growth forecasts amid declining shares and competitive pressure.
Despite the leadership change, Novo Nordisk's strategy remains unchanged, with confidence in its business plans and upcoming regulatory milestones, including an decision on oral Wegovy.